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AHR: Airway hyperresponsiveness
APC: Allophycocyanin
BAL: Bronchoalveolar lavage
ICOS: Inducible costimulator
ILC: Innate lymphoid cell
Lin: Lineage-specific marker
mTOR(C1/2): Mammalian target of rapamycin (complex 1/2)
PE: Phycoerythrin
PI3K: Phosphoinositide 3-kinase
rpS6: Ribosomal protein S6
S6K1: Ribosomal protein S6 kinase 1
TCR: T-cell receptor
TSLP: Thymic stromal lymphopoietin
WT: Wild-typeBackground: The IL-1 family cytokine IL-33 is involved in the
induction of airway inflammation in allergic patients and after
viral infection. Several cell types, including CD41 TH2 cells and
the recently described type 2 innate lymphoid cells (ILCs), are
targets for IL-33, yet the mechanisms by which this cytokine
modulates their activation are not clear.
Objectives: Our goal was to investigate a role for mammalian
target of rapamycin (mTOR) signaling in the activation of TH2
and ILC responses and the induction of airway inflammation by
IL-33.
Methods: We biochemically determined the effect of IL-33 on
mTOR activation in TH2 cells and ILCs and examined the
effect of this signaling pathway in vivo using a murine model of
IL-33–induced lung inflammation.
Results: We found that IL-33 induces mTOR activation through
p110d phosphoinositide 3-kinase and that blockade of the mTOR
pathway inhibited IL-33–induced IL-5 and IL-13 production by
TH2 cells and ILCs. Furthermore, use of a ribosomal protein S6
kinase 1 inhibitor implicated a role for ribosomal protein S6
kinase 1 in IL-33–induced mTOR-dependent cytokine
production. Intranasal administration of IL-33 to wild-type mice
induced airway inflammation, whereas adoptive transfer of wild-
type ILCs to IL-33 receptor–deficient (St22/2)mice recapitulated
this response. Importantly, coadministration of the mTOR
inhibitor rapamycin reduced IL-33–dependent ILC,
macrophage, and eosinophil accumulation; cytokine secretion;
and mucus deposition in the airways.
Conclusion: These data reveal a hitherto unrecognized role of
mTOR signaling in IL-33–driven, ILC-dependent inflammation
in vivo and suggest that manipulation of this pathway might
represent a target for therapeutic intervention for airway
inflammation. (J Allergy Clin Immunol 2012;130:1159-66.)
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Open access under CC BY license.The IL-1 family member IL-33 is a pleiotropic cytokine that
has been implicated in the induction of airway hyperresponsive-
ness (AHR) in allergic patients and after viral infection. Admin-
istration of IL-33 to mice induces airway inflammation
independently of adaptive immune responses,1 whereas increased
levels of expression of IL-33 in bronchial epithelia are associated
with increased severity of disease in asthmatic patients.2-4 An un-
derstanding of themechanisms and cellular targets of IL-33might
therefore lead to therapeutic intervention in patients with asthma
and allergic inflammation.5
IL-33 promotes CD41 T-cell differentiation to an atypical
TH2 phenotype characterized by the expression of IL-5 and
IL-13 but not IL-4.6 IL-33 also enhances the differentiation of ‘‘al-
ternatively activated’’ macrophages7,8 and stimulates mast
cell,9-12 basophil,13,14 and eosinophil13,15,16 responses. Interest-
ingly, a number of novel innate lymphoid cell (ILC) populations
that are important for the induction of type 2 responses17-20 and tis-
sue remodeling21 have recently been described. These cells are of
lymphoid origin22 and are characterized by their rapid production
of IL-5 and IL-13 in response to IL-25 and IL-33.17,19,20 Impor-
tantly, IL-33–driven type 2 ILCs were recently shown to contrib-
ute to AHR after viral infection and in protease-, ovalbumin-, and
glycolipid–induced murine models of airway inflammation.23-28
Recently, much work has focused on the requirement for the
mammalian target of rapamycin (mTOR) signaling pathway in
driving immune responses.29,30mTOR is a serine/threonine kinase
that links signaling in response to growth factors and nutrients and
is important for the regulation of cell growth, metabolism, and dif-
ferentiation. Interestingly, mTOR activity is important for the in-
duction of AHR by CD41 TH2 cells in response to house dust
mite allergens.31 By contrast, the role of mTOR in IL-33 signaling
and in type 2 ILC effector responses is unknown.
Here we describe an important role for mTOR signaling in
IL-33–dependent TH2 and ILC effector responses both in vitro1159
FIG 1. IL-33 induces mTOR activation in TH2 cells. A and B, Histograms
show phospho-rpS6 in D10.G4.1 orWT and St22/2 TH2 cells. CM, Complete
medium. C and D, Time course and dose response of IL-33–induced rpS6
phosphorylation in D10.G4.1 cells. E, Western blots of phospho-Akt and
S6K1. F, Relative levels of phospho-rpS6 in D10.G4.1 cells after stimulation
with IL-33 in the presence of no inhibitor (NI), rapamycin (Rap.; 100 nmol/L),
IC87114 (IC; 5 mmol/L), or PF-4708671 (S6K1i; 10 mmol/L). Error bars repre-
sent SDs (n 5 4).
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FIG 2. mTOR regulates IL-33–induced cytokine production. Effects of
rapamycin (Rap.; 100 nmol/L) on levels of IL-5 (A) and IL-13 (B) induced
by IL-33 6 IL-2. CM, Complete medium. *P < .05 and ***P < .001, unpaired
Student t test).
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1160 SALMOND ET ALand in vivo. IL-33 directly induced the activation of mTOR in a
phosphoinositide 3-kinase (PI3K) p110d–dependentmanner. Fur-
thermore, inhibition of mTOR reduced IL-33–driven IL-5 and
IL-13 expression by both TH2 cells and ILCs in vitro. We also
show that IL-33–induced airway inflammation was mediated by
ILCs and that rapamycin reduced ILC accumulation, macrophage
and eosinophil infiltration, cytokine secretion, and mucus deposi-
tion in the lung. These data uncover a hitherto unrecognized crit-
ical role for mTOR signaling in the biological effects of IL-33 and
the effector responses of type 2 ILCs.METHODS
Mice
BALB/c mice were from Harlan-Olac (Bicester, United Kingdom).
BALB/c St22/2 mice32 were bred and maintained at the University of
Glasgow. All experiments were performed in accordance with UK Home
Office guidelines.Cell lines
D10.G4.1 cells were maintained in complete RPMI 1640 medium (Gibco,
Carlsbad, Calif) containing 20 pg/mL IL-1a (R&D Systems, Minneapolis,
Minn) and 10% T-Stim culture supplement (BD Biosciences, San Jose, Calif).
For biochemical analysis, D10.G4.1 cells were incubated in complete mediumin the absence of IL-1a or T-Stim for 24 hours before stimulation. CD41 T
cells were purified from lymph nodes of BALB/c or St22/2 mice by means
of negative selection (Miltenyi Biotec, Bergisch Gladbach, Germany) to gen-
erate primary TH2 cells. Cells were stimulated on anti-CD3ε (BD PharMin-
gen, San Jose, Calif)–coated plates in the presence of anti-CD28 (BD
PharMingen), anti–IFN-g (R&D Systems), and 10 ng/mL recombinant IL-4
and IL-2 (R&D Systems) for 4 days. Cells were restimulated for 2 further
4-day rounds of polarization under similar conditions without IL-2. Before re-
stimulation, cells were incubated overnight in complete RPMI in the absence
of cytokines and T-cell receptor (TCR) stimulation.Intranasal IL-33 administration, isolation of ILCs,
and adoptive cell transfer
Mice were anesthetized with isoflurane and 30 mL of PBS 6 1 mg of IL-
336 1 mg/kg rapamycin inoculated into the nasal passage. For ILC isolation,
mice were treated for 5 days with IL-33. Lungs were collected on day 6 and
digested in 125 mg/mL Liberase TL and 100 mg/mL DNAse 1 (Roche
Diagnostics, Mannheim, Germany). Nonadherent cells were stained with
ST2–fluorescein isothiocyanate, lineage markers (B220, FcεRI, CD11b, and
CD3ε)–phycoerythrin (PE), CD278-PerCP/Cy5.5, CD45-Alexafluor 700, and
UVE/DEADfixable AquaDead cell stain (Life Technologies, Carlsbad, Calif)
and sorted with a BD FACS Aria. Cells were rested overnight before in vitro
analyses. For transfer, 106 ILCs in 30 mL of PBS were inoculated intranasally,
as described, followed by PBS 6 IL-33 6 rapamycin.Analysis of bronchoalveolar lavage fluid and lungs
Trachea were cannulated, 800 mL of PBS was flushed into the lungs, and
the fluid was collected. Bronchoalveolar lavage (BAL) fluid was centrifuged,
and supernatants were collected. Cell pellets were resuspended in PBS and
counted. Cells (105) were used for cytospin preparations and stained by using
the Romanovsky method (Raymond A Lamb, Eastborne, United Kingdom).
Cell morphology was assessed microscopically under oil immersion.
FIG 3. PI3K p110d and S6K1 inhibitors reduce IL-33–induced IL-13 produc-
tion. A, Comparison of the effects of rapamycin (Rap.; 100 nmol/L), IC87114
(5 mmol/L), and PF-4708671 (S6K1i; 10 mmol/L) on levels of IL-33–induced IL-
13 produced by TH2 cells. Error bars represent SDs (n 5 3-12). Data repre-
sent one of 3 repeated experiments. CM, Complete medium. ***P < .001,
unpaired Student t test. B, Schematic representation of the role of the
mTOR pathway in IL-33–induced cytokine production.
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Cells were preincubated in the presence or absence of 100 nmol/L rapamycin
(Calbiochem, Nottingham, United Kingdom), 100 nmol/L Torin-1 (Tocris
Bioscience, Bristol, United Kingdom), 5 mmol/L IC87114 (a gift from
Dr K. Okkenhaug, Babraham Institute, United Kingdom), or 10 mmol/L
ribosomal protein S6 kinase 1 (S6K1) inhibitor PF-4708671 (Sigma-Aldrich,
St Louis, Mo) for 30 minutes. Inhibitors were used at concentrations previously
determined as selective for intended targets.33-36 Cells were stimulated with
IL-33 (BioLegend, San Diego, Calif)6 IL-2, IL-7, or thymic stromal lympho-
poietin (TSLP), 10 ng/mLunless otherwise stated, for the time periods indicated.
Additional information on experimental procedures is included in the
Methods section in this article’s Online Repository at www.jacionline.org.
RESULTS
IL-33 induces mTOR activation through ST2 and
PI3K p110d
We tested the ability of IL-33 to induce phosphorylation of the
mTOR target ribosomal protein S6 (rpS6) in the murine TH2 cell
clone D10.G4.1. Intracellular staining and flow cytometry
indicated that IL-33 induced robust phosphorylation of rpS6
(Fig 1, A). Importantly, IL-33 also induced rpS6 phosphorylation
in primary TH2 cells derived from wild-type (WT) but not St2
2/2
mice (Fig 1, B). Dose-response and kinetic studies indicated that
as little as 40 pg/mL IL-33was sufficient to inducemaximal levels
of rpS6 phosphorylation that was apparent at 15 minutes and re-
mained high for at least 1 hour after stimulation of D10.G4.1 cells
(Fig 1, C and D). Furthermore, IL-33 induced phosphorylation of
the mTOR complex 1 (mTORC1) substrate S6K1 and the mTOR
complex 2 (mTORC2) substrate Akt (Fig 1, E).To test the IL-33–induced signaling pathway, resulting in
mTOR activation, we used a series of pharmacologic inhibitors.
Our previous report has shown that TCR-driven mTOR activation
requires the PI3K p110d isoform.36 Furthermore, IL-33 induces
activation of PI3K in vascular tissue37 and eosinophils.38 Pretreat-
ment of D10.G4.1 cells with the p110d-selective inhibitor
IC87114 reduced IL-33–induced rpS6 phosphorylation by 75%
(Fig 1, F) and markedly inhibited Akt phosphorylation (see Fig
E1, A, in this article’s Online Repository at www.jacionline.
org), indicating an upstream role for PI3K p110d in the activation
of both mTORC1 and mTORC2. Rapamycin completely blocked
rpS6 phosphorylation (Fig 1, F) but did not inhibit Akt phospho-
rylation (see Fig E1, B), confirming the selectivity of the drug for
mTORC1 in short-term assays.39 By contrast, the mTOR kinase
inhibitor Torin-1 completely prevented IL-33–induced rpS6,
S6K1, and Akt phosphorylation (see Fig E1, B). As expected, an
S6K1-specific inhibitor PF-470867135 blocked rpS6 phosphoryl-
ation (Fig 1,F) but did not affect Akt phosphorylation (see Fig E1,
A). Importantly, treatment of TH2 cells with rapamycin, Torin-1,
IC87114, or S6K1 did not affect canonical IL-33–induced nuclear
factor kB and p38 mitogen-activated protein kinase signaling
pathways, indicating the selectivity of the inhibitors (see Fig E1,
A and C). Together, these data indicate that IL-33 induces
mTOR activation and phosphorylation of downstream effector
proteins through ST2 signaling and activation of PI3K p110d.mTOR is required for optimal induction of IL-5 and
IL-13 production by IL-33
A role for mTOR in IL-33–induced TH2 cytokine production
was assessed. Primary TH2 effector cells were restimulated for
24 hours in the absence of TCR stimulation with IL-33 6 IL-2.
ELISA analysis indicated that IL-33 or IL-2 alone induced signif-
icant levels of IL-5 (Fig 2, A) and IL-13 (Fig 2, B) production.
However, a combination of IL-33 and IL-2 induced strongly in-
creased amounts of IL-5 and IL-13, indicating a synergistic
effect (Fig 2). Importantly, treatment of cells with rapamycin in-
hibited IL-5 production by 70% and IL-13 production by 50% in
response to IL-33 6 IL-2 (Fig 2), indicating an important
role for mTOR signaling in these processes. We performed
experiments to assess the role of mTOR in the effects of IL-
33 on TCR-induced polarization of naive T cells. Naive CD41
T cells were stimulated with CD3 and CD28
antibodies 6 IL-33 6 rapamycin for 4 days, and levels of cyto-
kines in tissue supernatants were measured. As previously
reported,6 IL-33 enhanced IL-5 and IL-13 levels (see Fig E2
in this article’s Online Repository at www.jacionline.org). Rapa-
mycin treatment profoundly inhibited levels of IL-5 and IL-13 ir-
respective of whether the cells had been stimulated in the
presence of IL-33 (see Fig E2), confirming the vital role for
mTOR in differentiation of naive T cells.40
To understand the mechanism by which rapamycin inhibited
cytokine production, we assessed levels of Il13mRNA. Quantita-
tive PCR analysis showed that levels of Il13 in TH2 cells peaked at
2 hours after stimulation with IL-331 IL-2 (see Fig E3, A, in this
article’s Online Repository at www.jacionline.org). Interestingly,
Il13mRNA levels were not affected by rapamycin treatment up to
at least 8 hours of IL-33 1 IL-2 stimulation (see Fig E3, A),
whereas differences in the levels of IL-13 protein in culture super-
natants were already apparent at this time point (see Fig E3, B).
Furthermore, Western blotting showed that rapamycin did not
FIG 4. Rapamycin reduces IL-33–induced airway inflammation. A, Effect of rapamycin (Rap; 1 mg/kg) on IL-
33–induced total BAL cell, eosinophil, and macrophage accumulation. Values are from individual mice, and
bars represent means. B, Levels of IL-5 and IL-13 in BAL fluid. C, Histologic analysis of lung sections after
hematoxylin and eosin (HE) or periodic acid–Schiff (PAS) staining. Scale bars5 200 mm. Data are represen-
tative of 3 to 8 mice per group. D, Histologic scores of cell infiltration and mucus deposition. Error bars rep-
resent SEMs. *P < .05, **P < .01, and ***P < 0.001, unpaired Student t test.
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did not affect mRNA stability through this protein (see Fig E3,C).
Finally, we tested the role of the upstream activator of mTOR,
PI3K p110d, and the mTORC1 effector S6K1 in IL-33–induced
cytokine production. Treatment of TH2 cells with the p110d in-
hibitor IC87114 partially inhibited IL-33–induced IL-13 produc-
tion (Fig 3, A), confirming a role for p110d in IL-33–driven
cytokine production. Similarly, incubation of cells with the
S6K1 inhibitor PF-4708671 reduced levels of IL-33–induced
IL-13 production by approximately 40% (Fig 3, A). However,
IC87114 and PF-4708671 were less potent suppressors of IL-13
production than rapamycin. Taken together, these data indicate
that mTOR activation is important for IL-33–induced cytokine
production and suggest that this process is, in part, mediated by
mTORC1-induced activation of S6K1 (Fig 3, B).Rapamycin reduces IL-33–induced airway
inflammation and cytokine production in vivo
Having determined an important role for mTOR in the induc-
tion of TH2 cell cytokine production, we sought to examine the
function of this signaling pathway in the induction of airway in-
flammation by IL-33 in vivo. We assessed the effects of intranasal
administration of recombinant IL-33 in the presence or absence of
rapamycin on 5 consecutive days to BALB/c mice. Analysis of
BAL fluid indicated that intranasal IL-33 induced the accumula-
tion of eosinophils and macrophages in the lungs (Fig 4, A).
Importantly, coadministration of rapamycin strongly reducedIL-33–induced eosinophil and, particularly, macrophage infiltra-
tion (Fig 4, A). Analysis of BAL fluid showed that IL-33 induced
high levels of IL-5 and IL-13 in the airways (Fig 4, B). Coadmin-
istration of rapamycin strongly inhibited IL-33–induced cytokine
production, confirming a requirement for mTOR in this process
in vivo (Fig 4, B).
Histologic analysis confirmed substantial cell infiltration into
the lungs of IL-33–treated mice (Fig 4, C). Furthermore, periodic
acid–Schiff staining of lung sections indicated large amounts of mu-
cus deposition after IL-33 administration (Fig 4, C). By contrast,
levels of cell infiltration and mucus deposition were reduced in
mice coadministered IL-33 and rapamycin (Fig 4, C and D). Taken
together, these data showapotent suppressive effect of themTOR in-
hibitor rapamycin on the induction of airway inflammation by IL-33.
Type 2 ILCs are responsible for IL-33–induced
cytokine production during airway inflammation
in vivo
To determine which cell type was responsible for IL-33–
induced cytokine production in the lungs, we performed multi-
parameter flow cytometry on cells from mice treated intranasally
with IL-33. Cells from lung digests were restimulated with
phorbol ester and ionomycin and stained for intracellular IL-5
(Fig 5, A) or IL-13 (see Fig E4, A, in this article’s Online
Repository at www.jacionline.org). Cells were further analyzed
for surface expression of lineage-specific markers (Lin),
including B220, CD11b, FcεRI, and CD3ε. The majority of
FIG 5. Type 2 ILCs are the predominant cytokine-producing population
induced by IL-33 in murine lungs, whereas rapamycin (Rap) reduces their
accumulation. A, Fluorescence-activated cell sorting analysis of IL-5–pro-
ducing cells present in lung digests. B, Effects of rapamycin on total ILCs,
IL-5–producing ILCs, and IL-13–producing ILCs. *P < .05, unpaired Student
t test. Error bars represent SDs (n 5 3-4 per group), and data represent one
of 3 repeated experiments.
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ysis of CD451Lin2 cells from the lungs of IL-33–treated mice in-
dicated that these cells did not express CD11c, NK1.1, TCRab, or
TCRgd but did express high levels of inducible costimulator
(ICOS), ST2, CD25, and CD127 and low levels of c-Kit (Fig 5,
A, see Fig E4), which is consistent with the phenotype of ILC pop-
ulations described recently by several independent groups.19,21
Furthermore, analysis of cell numbers showed that intranasal ad-
ministration of IL-33 potently induced the accumulation of
CD451Lin2ST21ICOS1 ILCs in the murine lung (Fig 5, B). In-
terestingly, coadministration of rapamycin dramatically reduced
ILC accumulation. Together these data show that IL-33 promotes
the accumulation of IL-5– and IL-13–producing type 2 ILCs in
the murine lung and that this process is regulated by the mTOR
signaling pathway.Rapamycin directly inhibits IL-33–induced ILC
effector function
Because rapamycin affected ILC accumulation in the lungs
(Fig 5,B), it was possible that the reduced levels of IL-33–induced
cytokines in BAL fluid (Fig 4, B) simply represented reduced ILC
cell numbers. To directly determine whether mTOR was impor-
tant for IL-33–driven ILC effector function, we sorted ILCs to
greater than 98% purity (see Fig E4, B) and tested the effects ofrapamycin in vitro. Western blot analysis confirmed that IL-33 in-
duced rpS6 phosphorylation in an mTOR-dependent manner in
ILCs (Fig 6, A). Furthermore, IL-33 alonewas sufficient to induce
production of IL-5 and IL-13 by ILCs in vitro (Fig 6, B), whereas
combinations of IL-33with either of the innate cytokines TSLP or
IL-7 were strongly synergistic (Fig 6, C). Importantly, rapamycin
potently reduced levels of IL-5 and IL-13 produced by ILCs in re-
sponse to IL-33 alone or in combination with TSLP or IL-7 (Fig 6,
B and C). However, rapamycin treatment did not affect basal or
IL-33–induced Il13 mRNA levels (Fig 6, D).
In further experiments the effects of IL-33, IL-7, and TSLP on
ILC proliferation were assessed. IL-33 alone induced very low
levels of proliferation in ILC cultures that were not significantly
affected by rapamycin (Fig 6, E). By contrast, TSLP and particu-
larly IL-7 potently stimulated ILC proliferation, whereas rapamy-
cin had a modest inhibitory effect (Fig 6, E). Taken together, these
data confirm an important and direct role for mTOR signaling in
IL-33–induced ILC cytokine production.Type 2 ILCs are sufficient to mediate IL-33–induced
airway inflammation
To determine whether ILCs were sufficient to induce airway
inflammation, we developed an adoptive cell transfer system in
which ST2-sufficient ILCs were transferred to ST2-deficient
hosts. Because ST2 is indispensable for responses to IL-33,41 this
approach allowed us to investigate the role of ILCs in airway in-
flammation without potential complications of direct effects of
IL-33 on other lung cell populations. Groups of St22/2 mice
were inoculated intranasally with 106 ILCs together with IL-33
or PBS. St22/2 mice receiving ILCs alone did not show signs
of airway inflammation. However, on administration of IL-33, to-
tal cell numbers in BAL fluid and lung digests were substantially
increased (Fig 7, A). Fluorescence-activated cell sorting analysis
of lung digests showed that numbers of St22/2 host eosinophils,
macrophages, and neutrophils were increased after intranasal
IL-33 administration (see Fig E5, A, in this article’s Online Re-
pository at www.jacionline.org). Furthermore, the numbers of do-
nor WT ILCs recovered from IL-33–treated mice were markedly
higher than those from control mice (see Fig E5, A). Levels of IL-
5 and IL-13 in the BAL fluid from IL-33–treated mice were also
strongly increased, confirming a role for type 2 ILCs in IL-33–in-
duced cytokine production in vivo (Fig 7,B). Hematoxylin and eo-
sin and periodic acid–Schiff staining of lung tissues from
recipient mice indicated that donorWT ILCswere sufficient to in-
duce high levels of cellular infiltration and mucus deposition after
administration of IL-33 (Fig 7, C, and see Fig E5, B). Together,
these data show that in the absence of additional IL-33–respon-
sive cells, ILCs are sufficient to induce leukocyte infiltration, cy-
tokine production, and mucus deposition in the lungs of mice in
response to IL-33.
Finally, experiments were performed to directly test the role of
mTOR in IL-33–driven ILC responses in vivo. WT ILCs were
transferred into St22/2 mice, and the recipients were then admin-
istered intranasal IL-336 rapamycin for 5 consecutive days. Ra-
pamycin reduced IL-33–induced ILC-dependent cellular
accumulation in the lungs of recipient mice (Fig 8, A). Rapamycin
reduced eosinophil, macrophage, and neutrophil cell numbers
in the lung tissues of recipient mice (Fig 8, B), whereas levels of
IL-5 and IL-13 in BAL fluid were also substantially lower
(Fig 8, C). Therefore these data demonstrate a direct regulatory
FIG 6. Rapamycin (Rap) directly inhibits ILC effector function. A, Western blots for phospho-rpS6 in ILCs.
Data represent one of 4 experiments. B and C, Effect of rapamycin (100 nmol/L) on IL-5 and IL-13 induced
by IL-33 (Fig 6, B) or IL-336 TSLP or IL-7 (Fig 6, C).D, Effect of rapamycin on IL-33–induced Il13mRNA levels.
Data represent one of 3 experiments. E, Effect of rapamycin on ILC proliferation induced by IL-33 6 TSLP or
IL-7. All error bars represent SDs (n 5 3), and all data represent one of at least 3 repeated experiments. CM,
Complete medium. * P < .05 and ***P < .001, Student t test.
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DISCUSSION
Data presented here provide direct evidence that activation of
the mTOR signaling pathway by IL-33 is important for stimulat-
ing the effector functions of both CD41 TH2 cells and type 2
ILCs. Our results have also identified ILCs as critical for the in-
duction of airway inflammation by IL-33 and a requirement for
mTOR in this process.
Results from several groups identified novel innate immune
cells involved in type 2 immune responses. Moro et al18 first de-
scribed an adipose-associated innate population in the murine
mesentery termed ‘‘natural helper cells.’’ This population was
characterized by production of IL-5, IL-6, and IL-13 and surface
expression of c-Kit, Sca-1, CD127, and ST2. The McKenzie and
Locksley laboratories described a similar population that ex-
panded in response to IL-25 and IL-33, produced large amounts
of IL-13, and was important for immunity to helminths.17,19 Sub-
sequently, the Umetsu and Stockinger laboratories reported an
important role for ILC populations in driving airway inflamma-
tion in mice.23,42 In contrast, Monticelli et al21 have reported
that a lung ILC population is important for airway remodeling
and maintenance of epithelial integrity and lung function after vi-
ral infection. Although the precise relationship between these cell
populations is not clear, these data have shown that phenotypi-
cally similar populations of ILCs are important in the induction
of protective type 2 immune responses in parasitic infections
and as mediators of both tissue homeostasis and pathologic in-
flammation in the lung.
In the present study we show that IL-33 directly expands the
lung ILC population, which mediates airway inflammation.
Importantly, we showed that ILCs were the predominant IL-5– andIL-13–producing cells in the lungs of IL-33–treated mice. ThusWT
ILCswere sufficient tomediate IL-33–induced airway inflammation
and induce granulocyte, eosinophil, and macrophage infiltration and
cytokine production on transfer to St22/2 mice.
It has become clear that IL-33 is critical for the activation of
type 2 ILCs. However, the signaling pathways induced by this
cytokine that are responsible for eliciting ILC effector responses
have not previously been identified. Our finding that IL-33
induced mTOR activation and that rapamycin potently inhibited
IL-33–induced ILC accumulation in the lungs, cytokine produc-
tion, and airway inflammation demonstrate a vital role for this
signaling pathway. We showed that mTOR was activated in
response to IL-33 in both TH2 cells and ILCs through a pathway
that involved PI3K p110d. We also showed that an S6K1 inhibitor
reduced IL-33–induced IL-13 production. Although activation of
S6K1 has long been linked to the induction of T-cell prolifera-
tion,43 little is known of the physiologic role of S6K1 in immune
responses. Our data suggest that mTOR regulates IL-33–depen-
dent cytokine production at least in part through the activation
of S6K1. Our studies also indicate that inhibition ofmTOR affects
IL-33–induced cytokine production independently of effects on
mRNA levels in both TH2 cells and ILCs. These data are consis-
tent with the well-documented role of mTORC1 in the transla-
tional regulation of gene expression. Thus S6K1 and additional
mTOR targets, including the 4E-binding proteins, are known to
regulate the rates of translation initiation.44
Recent data have identified human IL-33–responsive ILC
populations that are present in increased numbers in nasal polyps
of patients with chronic rhinosinusitis.20 Furthermore, increased
IL-33 expression in bronchial biopsy specimens has been sug-
gested as a clinical marker of severe asthma.2,3 Moreover, rapa-
mycin was effective at inhibiting T-cell responses from
glucocorticoid-refractory asthmatic patients,45 whereas mTOR
FIG 8. Rapamycin (Rap) inhibits ILC-induced airway inflammation. A, Cell
numbers in BAL fluid and lung digests. Horizontal bars represent means,
and data represent values from individual mice (4-5 per group) from one
of 3 repeated experiments. B, Eosinophil, macrophage, neutrophil, and do-
nor ILC cell numbers in lung digests. C, Levels of IL-33–induced, ILC-
dependent IL-5 and IL-13 in BAL fluid. Error bars represent SDs (n 5 4-5).
*P < .05, **P < .01, and ***P < .001, all unpaired Student t test.
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FIG 7. ILCs are sufficient to mediate IL-33–induced airway inflammation. A,
Cell counts in BAL fluid and lung digests from IL-33–treated St22/2mice re-
ceiving WT ILCs. B, Levels of IL-5 and IL-13 in BAL fluid. Values represent
means 6 SDs of 3 to 4 mice. C, Histologic scores of lung sections. Error
bars represent SEMs (n 5 7-8). *P < .05, **P < .01, and ***P < .001.
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vival.46 Therefore our finding that rapamycin potently suppressed
IL-33–induced ILC-mediated lung inflammation advances the
field considerably and, furthermore, suggests that manipulation
of themTORpathwaymight prove beneficial in airway inflamma-
tion in human disease.
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Key messages
d This study identifies an important role for the mTOR sig-
naling pathway in the biological responses of CD41 TH2
cells and ILCs elicited by IL-33.
d Abrogation of mTOR signaling with rapamycin reduces
TH2 cell and ILC cytokine production in vitro and allevi-
ates IL-33–induced airway inflammation in vivo by reduc-
ing ILC accumulation, cytokine secretion, eosinophilia,
and mucus deposition in the airways.
d These studies provide a molecular mechanism and iden-
tify ILCs as sufficient for the induction of airway inflam-
mation by IL-33.REFERENCES
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Flow cytometry
For phospho-rpS6 analysis, cells were fixed in 2% formaldehyde, washed
in PBS, permeabilized, and stored in 90% methanol until analysis. For
cytokine staining, lung cells were fixed and permeabilized in Cytofix/
Cytoperm buffer and washed in Perm/wash buffer (both from BD Biosci-
ences). The following antibodies were used: B220-PE, CD11b-PE, CD117–
allophycocyanin (APC), CD25-PE, TCRb-Biotin, IL-5–APC (all from BD
Biosciences), CD4-PE/Cy7, CD11c-APC, NK1.1-PE, CD127-APC, TCRgd-
APC, FcεRIa-PE, CD45–AlexaFluor 700, CD3ε-PE, IL-13–AlexaFluor 647
(all from eBioscience, San Diego, Calif), CD278-PerCP/Cy5.5 (BioLegend),
rpS6 Ser240/4-AlexaFluor 488 (Cell Signaling Technology, Danvers, Mass),
and ST2–fluorescein isothiocyanate (MD Biosciences, St Paul, Minn). Data
were acquired by using FACSCalibur, FACSAria, or LSRII flow cytometers
(all from BD Biosciences) and analyzed with FlowJo software (TreeStar,
Ashland, Ore).
Western blotting
Lysates were prepared in RIPA buffer and NuPage sample buffer
(Invitrogen, Carlsbad, Calif). Cell equivalents (2.5 Χ 105) were loaded on
NuPage minigels (Invitrogen), and proteins were separated by means of
electrophoresis and transferred to nitrocellulose by using the I-Blot dry
transfer system (Invitrogen). Membranes were blocked in 5% BSA
before blotting with phospho-S6K1 Ser421/Thr424, phospho-Akt Ser473,
phospho-rpS6 Ser240/4, Akt (all from Cell Signaling Technology), and
tubulin (Santa Cruz Biotechnology, Santa Cruz, Calif) antibodies.
Horseradish peroxidase–conjugated secondary antibodies were from CellSignaling. Membranes were incubated with chemiluminescent substrate
(Amersham, Piscataway, NJ) and exposed to Medical X-Ray film (Kodak,
Rochester, NY).
Cytokine ELISA
TH2 cells (53 10
4 cells) or ILCs (13 105 cells) were cultured in triplicate
wells, as indicated, for 24 hours. Cytokines in culture supernatants or BAL
fluid were quantified by means of ELISAwith IL-5 capture and biotinylated
detection (both from BD Biosciences) or murine IL-13-Ready-SET-Go!
(eBioscience).
RNA isolation and quantitative PCR
TH2 cells (10
6) or ILCs were preincubated in the presence or absence of 50
nmol/L rapamycin before stimulation with IL-336 IL-2 for 4 hours. RNAwas
prepared by using RNeasy mini-kits (Qiagen, Hilden, Germany), and cDNA
was generated with MultiScribe reverse transcriptase (Applied Biosystems,
Foster City, Calif). TaqMan probes, primer sets, and an ABI Prism 7900 Se-
quence Detection System instrument real-time PCR system (Applied Biosys-
tems) were used for real-time quantitative PCR amplification of cDNA. Levels
of Il13 were normalized to those of Hprt.
Cell proliferation
TH2 cells or ILCs (5 3 10
4 cells) were cultured in the presence of
IL-336 IL-2, IL-7, or TSLP (all 10 ng/mL)6 rapamycin (50 nmol/L). Cells
were pulsed with 0.037 MBq of tritiated thymidine in the last 16 hours of a
72-hour culture.
FIG E1. Efficacy and specificity of pharmacologic inhibitors. A, Effects of IC87114 (IC; 5 mmol/L) and S6K1
inhibitor (S6K1i; 10 mmol/L) on IkBa degradation, p38, and Akt phosphorylation. B and C, Effects of rapamy-
cin (Rap; 100 nmol/L) and Torin-1 (Tor1; 100 nmol/L) on IL-33–induced S6K1, rpS6, and Akt phosphorylation
(Fig E1, B) and p38 activation and IkBa degradation (Fig E1, C). D, Dose-response effects of rapamycin on
IL-33–induced rpS6 phosphorylation.
J ALLERGY CLIN IMMUNOL
NOVEMBER 2012
1166.e2 SALMOND ET AL
CD3/28 CD3/28/IL33
0
1000
2000
3000
4000
5000
6000
7000
No inhib Rapamycin
CD3/28 CD3/28/IL33
0
5000
10000
15000
20000
25000
No inhib Rapamycin
A 
B 
I
L
-
5
 
(
p
g
/
m
l
)
I
L
-
1
3
 
(
p
g
/
m
l
)
FIG E2. Rapamycin inhibits the effects of IL-33 on TCR-induced differenti-
ation. Naive T cells were stimulated with CD3 and CD28 in the presence or
absence of IL-33 and rapamycin (100 nmol/L). Levels of IL-5 (A) and IL-13 (B)
in supernatants were assessed by means of ELISA. Error bars represent
SEMs (n 5 3).
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FIG E3. Rapamycin inhibits IL-13 protein production independently of
effects on Il13 mRNA or HuR expression. A and B, Bar charts show levels
of Il13 mRNA expression in TH2 cells (Fig E3, A) or protein in supernatants
(Fig E3, B) after stimulation with IL-33 1 IL-2 6 rapamcycin (Rap; 100 nmol/
L). Data depict values from 1 of 3 repeated experiments, and error bars rep-
resent SDs (n5 2). C,Western blot showing levels of HuR expression in TH2
cells stimulated as described above.
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FIG E4. Phenotypic analysis of type 2 ILCs. A, Fluorescence-activated cell sorting analysis demonstrating
IL-33–elicited IL-13–producing cells present in lung digests are predominantly Lin2CD451ICOS1ST21
ILCs. B, Dot plots depict proportions of gated CD451Lin2 type 2 ILCs before and after cell sorting, as as-
sessed by analysis of ST2 and ICOS expression. C, Histograms showing cell-surface expression of CD11c,
NK1.1, TCRgd, TCRb, CD25, CD127, and c-Kit on purified type 2 ILCs. Shaded histograms represent isotype
controls.
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FIG E5. TransferredWT ILCs facilitate IL-33–induced inflammation in St22/2
recipients. A, Eosinophil, macrophage, neutrophil, and donor ILC numbers
in BAL fluid and lung digests from IL-33–treated St22/2 mice receiving WT
ILCs. Horizontal bars represent means, and data represent individual ani-
mals from 2 pooled experiments. B, Histologic analysis of lung sections
stained with hematoxylin and eosin (HE) and periodic acid–Schiff (PAS).
Pictures depict representative fields from 1 of 7 to 8 mice per group. Scale
bars 5 200 mm. *P < .05 and **P < .01.
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